鳳凰光學(600071.SH):重大資產重組事項獲中國電科批覆
格隆匯11月18日丨鳳凰光學(600071.SH)公佈,公司於2019年11月18日收到了中國電子科技集團有限公司下發的《中國電科關於浙江海康科技有限公司智能控制器業務資產組協議轉讓相關事項的批覆》(電科資函[2019]129號),同意中電海康集團有限公司下屬控股子公司浙江海康科技有限公司將所屬智能控制器業務相關資產以非公開協議轉讓方式,轉讓至公司全資子公司江西鳳凰光學科技有限公司,具體轉讓價格以經集團公司備案的相關資產評估結果為準,為4.15億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.